Effect of glutaminase inhibition on cancer-induced bone pain

References

• HanahanD, WeinbergRA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.01321376230
   PubMed Web of Science ®Google Scholar
• Vander HeidenMG, DeBerardinisRJ. Understanding the intersections between metabolism and cancer biology. Cell. 2017;168(4):657–669. doi:10.1016/j.cell.2016.12.03928187287
   PubMed Web of Science ®Google Scholar
• HosiosAM, HechtVC, DanaiLV, et al. Amino acids rather than glucose account for the majority of cell mass in proliferating mammalian cells. Dev Cell. 2016;36(5):540–549. doi:10.1016/j.devcel.2016.02.01226954548
   PubMed Web of Science ®Google Scholar
• AlberghinaL, GaglioD. Redox control of glutamine utilization in cancer. Cell Death Dis. 2014;5:e1561. doi:10.1038/cddis.2014.51325476909
   PubMed Web of Science ®Google Scholar
• WiseDR, ThompsonCB. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci. 2010;35(8):427–433. doi:10.1016/j.tibs.2010.05.00320570523
   PubMed Web of Science ®Google Scholar
• MercadanteS. Malignant bone pain: pathophysiology and treatment. Pain. 1997;69(1–2):1–18.9060007
   PubMed Web of Science ®Google Scholar
• SkerryTM. The role of glutamate in the regulation of bone mass and architecture. J Musculoskelet Neuronal Interact. 2008;8(2):166–173.18622085
   PubMedGoogle Scholar
• SeidlitzEP, SharmaMK, SinghG. Extracellular glutamate alters mature osteoclast and osteoblast functions. Can J Physiol Pharmacol. 2010;88(9):929–936. doi:10.1139/y10-07020921979
   PubMed Web of Science ®Google Scholar
• FazzariJ, BalenkoMD, ZacalN, SinghG. Identification of capsazepine as a novel inhibitor of system xc- and cancer-induced bone pain. J Pain Res. 2017;10:915–925. doi:10.2147/JPR.S12504528458574
   PubMed Web of Science ®Google Scholar
• UngardRG, SeidlitzEP, SinghG. Inhibition of breast cancer-cell glutamate release with sulfasalazine limits cancer-induced bone pain. Pain. 2014;155(1):28–36. doi:10.1016/j.pain.2013.08.03023999057
   PubMed Web of Science ®Google Scholar
• CarrascosaJM, MartínezP, de CastroIN. Nitrogen movement between host and tumor in mice inoculated with ehrlich ascitic tumor cells. Cancer Res. 1984;44(9):3831–3835.6146402
   PubMed Web of Science ®Google Scholar
• KungH-N, MarksJR, ChiJ-T. Glutamine synthetase is a genetic determinant of cell type-specific glutamine independence in breast epithelia. PLoS Genet. 2011;7(8):e1002229. doi:10.1371/journal.pgen.100222921852960
   PubMed Web of Science ®Google Scholar
• TimmermanLA, HoltonT, YunevaM, et al. Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell. 2013;24(4):450–465. doi:10.1016/j.ccr.2013.08.02024094812
   PubMed Web of Science ®Google Scholar
• WeinbergF, HamanakaR, WheatonWW, et al. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci USA. 2010;107(19):8788–8793. doi:10.1073/pnas.100342810720421486
   PubMed Web of Science ®Google Scholar
• SonJ, LyssiotisCA, YingH, et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature. 2013;496(7443):101–105. doi:10.1038/nature1204023535601
   PubMed Web of Science ®Google Scholar
• AltmanBJ, StineZE, DangCV. From Krebs to clinic: glutamine metabolism to cancer therapy. Nat Rev Cancer. 2016;16(10):619–634. doi:10.1038/nrc.2016.7127492215
   PubMed Web of Science ®Google Scholar
• YangM, VousdenKH. Serine and one-carbon metabolism in cancer. Nat Rev Cancer. 2016;16(10):650–662. doi:10.1038/nrc.2016.8127634448
   PubMed Web of Science ®Google Scholar
• BhutiaYD, BabuE, RamachandranS, GanapathyV. Amino acid transporters in cancer and their relevance to “glutamine addiction”: novel targets for the design of a new class of anticancer drugs. Cancer Res. 2015;75(9):1782–1788. doi:10.1158/0008-5472.CAN-14-374525855379
   PubMed Web of Science ®Google Scholar
• GrossMI, DemoSD, DennisonJB, et al. Antitumor activity of the glutaminase inhibitor cb-839 in triple-negative breast cancer. Mol Cancer Ther. 2014;13(4):890–901. doi:10.1158/1535-7163.MCT-13-087024523301
   PubMed Web of Science ®Google Scholar
• QuadrosAU, PintoLG, FonsecaMM, KusudaR, CunhaFQ, CunhaTM. Dynamic weight bearing is an efficient and predictable method for evaluation of arthritic nociception and its pathophysiological mechanisms in mice. Sci Rep. 2015;5:14648. doi:10.1038/srep1464826511791
   PubMed Web of Science ®Google Scholar
• MuirA, DanaiLV, GuiDY, WaingartenCY, LewisCA, Vander HeidenMG. Environmental cystine drives glutamine anaplerosis and sensitizes cancer cells to glutaminase inhibition. Elife. 2017;6. doi:10.7554/eLife.27713
   Web of Science ®Google Scholar
• ShinC-S, MishraP, WatrousJD, et al. The glutamate/cystine xCT antiporter antagonizes glutamine metabolism and reduces nutrient flexibility. Nat Commun. 2017;8:15074. doi:10.1038/ncomms1507428429737
   PubMed Web of Science ®Google Scholar
• GuY, AlbuquerqueCP, BraasD, et al. mTORC2 regulates amino acid metabolism in cancer by phosphorylation of the cystine-glutamate antiporter xCT. Mol Cell. 2017;67(1):128–138.e7. doi:10.1016/j.molcel.2017.05.03028648777
   PubMed Web of Science ®Google Scholar
• SayinVI, LeBoeufSE, SinghSX, et al. Activation of the NRF2 antioxidant program generates an imbalance in central carbon metabolism in cancer. eLife Sciences. 2017;6:e28083. doi:10.7554/eLife.28083
   Web of Science ®Google Scholar
• BudcziesJ, BrockmöllerSF, MüllerBM, et al. Comparative metabolomics of estrogen receptor positive and estrogen receptor negative breast cancer: alterations in glutamine and beta-alanine metabolism. J Proteomics. 2013;94:279–288. doi:10.1016/j.jprot.2013.10.00224125731
   PubMed Web of Science ®Google Scholar
• BudcziesJ, PfitznerBM, GyörffyB, et al. Glutamate enrichment as new diagnostic opportunity in breast cancer. Int J Cancer. 2015;136(7):1619–1628. doi:10.1002/ijc.2915225155347
   PubMed Web of Science ®Google Scholar
• LampaM, ArltH, HeT, et al. Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition. PLoS One. 2017;12(9):e0185092. doi:10.1371/journal.pone.018509228950000
   PubMed Web of Science ®Google Scholar
• BiancurDE, PauloJA, MałachowskaB, et al. Compensatory metabolic networks in pancreatic cancers upon perturbation of glutamine metabolism. Nat Commun. 2017;8:15965. doi:10.1038/ncomms1596528671190
   PubMed Web of Science ®Google Scholar
• ChengT, SudderthJ, YangC, et al. Pyruvate carboxylase is required for glutamine-independent growth of tumor cells. PNAS. 2011;108(21):8674–8679.21555572
   PubMed Web of Science ®Google Scholar
• YangC, KoB, HensleyCT, et al. Glutamine oxidation maintains the TCA cycle and cell survival during impaired mitochondrial pyruvate transport. Mol Cell. 2014;56(3):414–424. doi:10.1016/j.molcel.2014.09.02525458842
   PubMed Web of Science ®Google Scholar
• GaglioD, MetalloCM, GameiroPA, et al. Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth. Mol Syst Biol. 2011;7:523. doi:10.1038/msb.2011.5621847114
   PubMed Web of Science ®Google Scholar
• WhillierS, GarciaB, ChapmanBE, KuchelPW, RaftosJE. Glutamine and α-ketoglutarate as glutamate sources for glutathione synthesis in human erythrocytes. Febs J. 2011;278(17):3152–3163. doi:10.1111/j.1742-4658.2011.08241.x21749648
   PubMed Web of Science ®Google Scholar